Loading...
Results from two large studies provide additional information on the association between hormone therapy (HT) and breast cancer risk.
In the first study, from the Women’s Health Initiative, women who had undergone hysterectomies (age range, 50–79) received either conjugated equine estrogen (0.625 mg daily) or placebo, for an average of 7.1 years. As reported in an earlier analysis (Journal Watch Apr 27 2004), the incidence of invasive breast cancer was not higher in the estrogen group. In fact, among adherent women, breast cancer incidence was significantly lower in the estrogen group than in the placebo group (hazard ratio, 0.67). Estrogen use was associated with a higher rate of abnormal mammography findings that required short-term follow…